logo
  

Acceleron Pharma Reports Positive Topline Results From PULSAR Trial

Acceleron Pharma Inc. (XLRN) announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial
hypertension. In the trial, sotatercept showed a statistically significant reduction in pulmonary vascular resistance, the trial's primary endpoint, at week 24 versus placebo.

The company plans to present a detailed review of the topline results from the
PULSAR Phase 2 trial of sotatercept at a medical conference later in the current year.

Shares of Acceleron Pharma Inc. were up nearly 70% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the fourth quarter on Thursday, professional services company Accenture Plc (ACN) initiated earnings and revenue growth outlook for the full-year 2022, above analysts' estimates and also provided revenue outlook for the first quarter. For fiscal 2022, the company... Impossible Foods Inc., a plant-based meat maker, is bringing its new plant-based pork product to the restaurants in U.S., Hong Kong and Singapore. Starting Thursday, Impossible pork will be available at Momofuku Ssäm Bar in Manhattan, New York City. It will serve Spicy Rice Cakes with Impossible Pork Ragu. Restaurants across the U.S. and Hong Kong can now order Impossible Pork for their menus. Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking.
Follow RTT